Product Code: GVR-2-68038-352-2
Single Cell Genome Sequencing Market Growth & Trends:
The global single cell genome sequencing market size is anticipated to reach USD 7.55 billion by 2030, according to a new report by Grand View Research, Inc.. The market is projected to grow at a CAGR of 16.1% from 2023 to 2030. Factor such as the increasing prevalence of chronic diseases like cancer, diabetes, and arthritis; advanced technology coupled with the latest collaborative efforts; increased investments in R&D; and rising geriatric population are anticipated to drive the market growth over the forecast period.
Active participation and contribution of market players toward product upgradation play an important role in the growth of the market. Increasing number of collaborations and strategic alliances between companies are fostering the development of a collaborative portfolio in the system. Moreover, the emergence of next-generation sequencing (NGS) has helped the market gain tremendous traction over the past few years. Earlier, single-cell genome sequencing market was dominated by PCR and microarray technologies. However, qPCR and NGS are increasingly emerging as the preferred technologies.
Furthermore, the rising number of single-cell genome sequencing centers & associated facilities worldwide is fostering growth prospects. The main objective of such entities is to develop novel single-cell genome sequencing-based applications and methods. These centers are also playing a major role in introducing advanced tools & instruments for scientific communities of various regions. In addition, public-private collaborations among governments, companies, and research institutions related to space are expected to promote more research initiatives. Various funding grants by NIH and private players such as Mission Bio are escalating the growth of the market.
Single Cell Genome Sequencing Market Report Highlights:
- Based on product type, the instruments segment dominated the market in 2022, with a revenue share of 57.43%. This domination can be largely attributed to the increased development and adoption of technologically advanced instruments
- Based on technology, PCR dominated the market in 2022, with a revenue share of 27.77%. Due to heavy investments in R&D, PCR is a widely recognized technology in the field of genome sequencing, highly coveted by market leaders and research institutes
- Based on workflow, the genomic analysis segment dominated the market in 2022, with a revenue share of 69.08%. This segment is also forecasted to have the fastest CAGR. This dominance can be attributed to the recent surge in funding for research and development capabilities and the widespread adoption of genomic analysis products
- Based on disease area, the cancer segment dominated the market in 2022 with a market share of 34.95%. The increasing prevalence of prostate, colorectal, and breast cancer is projected to generate lucrative opportunities for market growth.
- Based on application, the circulating tumor cells (CTCs) segment dominated the market in 2022, with a revenue share of 28.45%. This is due to the growing clinical application of CTCs as biomarkers for cancer detection
- Based on region, North America dominated the market in 2022 with a revenue share of 46.38%. owing to the extensive research and development activities, and the presence of a significant number of regional players. Asia Pacific region is anticipated to witness the fastest CAGR of 17.4% due to the rising geriatric population, leading to an increase in patients suffering from chronic diseases
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment definitions
- 1.1.1.1. Product segment
- 1.1.1.2. Workflow segment
- 1.1.1.3. Application segment
- 1.1.1.4. Technology segment
- 1.1.1.5. Disease Area segment
- 1.1.1.6. End-use segment
- 1.1.2. Regional Scope
- 1.1.3. Estimates and forecast time.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.4. Information Or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market formulation and validation
- 1.6. Objectives
- 1.6.1. Objective 1
- 1.6.2. Objective 2
- 1.6.3. Objective 3
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Product Launches by Market Players
- 3.2.1.2. Increasing Prevalence of Cancer
- 3.2.1.3. High R&D in the Single Cell Genomics Space
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Costs of Genome Sequencing Instruments
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Type Business Analysis
- 4.1. Single Cell Genome Sequencing Market: Product Type Movement Analysis
- 4.2. Instruments
- 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
- 4.3. Reagents
- 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
Chapter 5. Technology Business Analysis
- 5.1. Single Cell Genome Sequencing Market: Technology Movement Analysis
- 5.2. NGS
- 5.2.1. NGS Market, 2018 - 2030 (USD Million)
- 5.3. PCR
- 5.3.1. PCR Market, 2018 - 2030 (USD Million)
- 5.4. qPCR
- 5.4.1. qPCR Market, 2018 - 2030 (USD Million)
- 5.5. Microarray
- 5.5.1. Microarray Market, 2018 - 2030 (USD Million)
- 5.6. MDA
- 5.6.1. MDA Market, 2018 - 2030 (USD Million)
Chapter 6. Workflow Business Analysis
- 6.1. Single Cell Genome Sequencing Market: Workflow Movement Analysis
- 6.2. Genomic Analysis
- 6.2.1. Genomic Analysis Market, 2018 - 2030 (USD Million)
- 6.3. Single Cell Isolation
- 6.3.1. Single Cell Isolation Market, 2018 - 2030 (USD Million)
- 6.4. Sample Preparation
- 6.4.1. Sample Preparation Market, 2018 - 2030 (USD Million)
Chapter 7. Disease Area Business Analysis
- 7.1. Single Cell Genome Sequencing Market: Disease Area Movement Analysis
- 7.2. Cancer
- 7.2.1. Cancer Market, 2018 - 2030 (USD Million)
- 7.3. Immunology
- 7.3.1. Immunology Market, 2018 - 2030 (USD Million)
- 7.4. Prenatal Diagnosis
- 7.4.1. Prenatal Diagnosis Market, 2018 - 2030 (USD Million)
- 7.5. Neurobiology
- 7.5.1. Neurobiology Market, 2018 - 2030 (USD Million)
- 7.6. Microbiology
- 7.6.1. Microbiology Market, 2018 - 2030 (USD Million)
- 7.7. Others
- 7.7.1. Other Disease Areas Market, 2018 - 2030 (USD Million)
Chapter 8. Application Business Analysis
- 8.1. Single Cell Genome Sequencing Market: Application Movement Analysis
- 8.2. Circulating Cells
- 8.2.1. Circulating Cells Market, 2018 - 2030 (USD Million)
- 8.3. Cell Differentiation/Reprogramming
- 8.3.1. Cell Differentiation/Reprogramming Market, 2018 - 2030 (USD Million)
- 8.4. Genomic Variation
- 8.4.1. Genomic Variation Market, 2018 - 2030 (USD Million)
- 8.5. Subpopulation Characterization
- 8.5.1. Subpopulation Characterization Market, 2018 - 2030 (USD Million)
- 8.6. Others
- 8.6.1. Other Applications Market, 2018 - 2030 (USD Million)
Chapter 9. End-use Business Analysis
- 9.1. Single Cell Genome Sequencing Market: End-use Movement Analysis
- 9.2. Academic & Research Laboratories
- 9.2.1. Academic & Research Laboratories Market, 2018 - 2030 (USD Million)
- 9.3. Biotechnology & Biopharmaceutical Companies
- 9.3.1. Biotechnology & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
- 9.4. Clinics
- 9.4.1. Clinics Market, 2018 - 2030 (USD Million)
- 9.5. Others
- 9.5.1. Other End-uses Market, 2018 - 2030 (USD Million)
Chapter 10. Regional Business Analysis
- 10.1. Single Cell Genome Sequencing Market Share, By Region, 2022 & 2030
- 10.2. North America
- 10.2.1. SWOT Analysis
- 10.2.2. North America Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.2.3. U.S.
- 10.2.3.1. Key Country Dynamics
- 10.2.3.2. Target Disease Prevalence
- 10.2.3.3. Competitive Scenario
- 10.2.3.4. Regulatory Framework
- 10.2.3.5. U.S. Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.2.4. Canada
- 10.2.4.1. Key Country Dynamics
- 10.2.4.2. Target Disease Prevalence
- 10.2.4.3. Competitive Scenario
- 10.2.4.4. Regulatory Framework
- 10.2.4.5. Canada Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3. Europe
- 10.3.1. SWOT Analysis
- 10.3.2. Europe Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.3. UK
- 10.3.3.1. Key Country Dynamics
- 10.3.3.2. Target Disease Prevalence
- 10.3.3.3. Competitive Scenario
- 10.3.3.4. Regulatory Framework
- 10.3.3.5. UK Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.4. Germany
- 10.3.4.1. Key Country Dynamics
- 10.3.4.2. Target Disease Prevalence
- 10.3.4.3. Competitive Scenario
- 10.3.4.4. Regulatory Framework
- 10.3.4.5. Germany Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.5. France
- 10.3.5.1. Key Country Dynamics
- 10.3.5.2. Target Disease Prevalence
- 10.3.5.3. Competitive Scenario
- 10.3.5.4. Regulatory Framework
- 10.3.5.5. France Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.6. Italy
- 10.3.6.1. Key Country Dynamics
- 10.3.6.2. Target Disease Prevalence
- 10.3.6.3. Competitive Scenario
- 10.3.6.4. Regulatory Framework
- 10.3.6.5. Italy Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.7. Spain
- 10.3.7.1. Key Country Dynamics
- 10.3.7.2. Target Disease Prevalence
- 10.3.7.3. Competitive Scenario
- 10.3.7.4. Regulatory Framework
- 10.3.7.5. Spain Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.8. Denmark
- 10.3.8.1. Key Country Dynamics
- 10.3.8.2. Target Disease Prevalence
- 10.3.8.3. Competitive Scenario
- 10.3.8.4. Regulatory Framework
- 10.3.8.5. Denmark Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.9. Sweden
- 10.3.9.1. Key Country Dynamics
- 10.3.9.2. Target Disease Prevalence
- 10.3.9.3. Competitive Scenario
- 10.3.9.4. Regulatory Framework
- 10.3.9.5. Sweden Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.3.10. Norway
- 10.3.10.1. Key Country Dynamics
- 10.3.10.2. Target Disease Prevalence
- 10.3.10.3. Competitive Scenario
- 10.3.10.4. Regulatory Framework
- 10.3.10.5. Norway Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4. Asia Pacific
- 10.4.1. SWOT Analysis
- 10.4.2. Asia Pacific Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.3. Japan
- 10.4.3.1. Key Country Dynamics
- 10.4.3.2. Target Disease Prevalence
- 10.4.3.3. Competitive Scenario
- 10.4.3.4. Regulatory Framework
- 10.4.3.5. Japan Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.4. China
- 10.4.4.1. Key Country Dynamics
- 10.4.4.2. Target Disease Prevalence
- 10.4.4.3. Competitive Scenario
- 10.4.4.4. Regulatory Framework
- 10.4.4.5. China Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.5. India
- 10.4.5.1. Key Country Dynamics
- 10.4.5.2. Target Disease Prevalence
- 10.4.5.3. Competitive Scenario
- 10.4.5.4. Regulatory Framework
- 10.4.5.5. India Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.6. Australia
- 10.4.6.1. Key Country Dynamics
- 10.4.6.2. Target Disease Prevalence
- 10.4.6.3. Competitive Scenario
- 10.4.6.4. Regulatory Framework
- 10.4.6.5. Australia Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.7. Thailand
- 10.4.7.1. Key Country Dynamics
- 10.4.7.2. Target Disease Prevalence
- 10.4.7.3. Competitive Scenario
- 10.4.7.4. Regulatory Framework
- 10.4.7.5. Thailand Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.4.8. South Korea
- 10.4.8.1. Key Country Dynamics
- 10.4.8.2. Target Disease Prevalence
- 10.4.8.3. Competitive Scenario
- 10.4.8.4. Regulatory Framework
- 10.4.8.5. South Korea Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.5. Latin America
- 10.5.1. SWOT Analysis
- 10.5.2. Latin America Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.5.3. Brazil
- 10.5.3.1. Key Country Dynamics
- 10.5.3.2. Target Disease Prevalence
- 10.5.3.3. Competitive Scenario
- 10.5.3.4. Regulatory Framework
- 10.5.3.5. Brazil Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.5.4. Mexico
- 10.5.4.1. Key Country Dynamics
- 10.5.4.2. Target Disease Prevalence
- 10.5.4.3. Competitive Scenario
- 10.5.4.4. Regulatory Framework
- 10.5.4.5. Mexico Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.5.5. Argentina
- 10.5.5.1. Key Country Dynamics
- 10.5.5.2. Target Disease Prevalence
- 10.5.5.3. Competitive Scenario
- 10.5.5.4. Regulatory Framework
- 10.5.5.5. Argentina Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.6. MEA
- 10.6.1. SWOT Analysis
- 10.6.2. MEA Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.6.3. South Africa
- 10.6.3.1. Key Country Dynamics
- 10.6.3.2. Target Disease Prevalence
- 10.6.3.3. Competitive Scenario
- 10.6.3.4. Regulatory Framework
- 10.6.3.5. South Africa Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.6.4. Saudi Arabia
- 10.6.4.1. Key Country Dynamics
- 10.6.4.2. Target Disease Prevalence
- 10.6.4.3. Competitive Scenario
- 10.6.4.4. Regulatory Framework
- 10.6.4.5. Saudi Arabia Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.6.5. UAE
- 10.6.5.1. Key Country Dynamics
- 10.6.5.2. Target Disease Prevalence
- 10.6.5.3. Competitive Scenario
- 10.6.5.4. Regulatory Framework
- 10.6.5.5. UAE Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
- 10.6.6. Kuwait
- 10.6.6.1. Key Country Dynamics
- 10.6.6.2. Target Disease Prevalence
- 10.6.6.3. Competitive Scenario
- 10.6.6.4. Regulatory Framework
- 10.6.6.5. Kuwait Single Cell Genome Sequencing Market, 2018 - 2030 (USD Million)
Chapter 11. Competitive Landscape
- 11.1. Company Categorization
- 11.2. Strategy Mapping
- 11.3. Company Market Share Analysis, 2022
- 11.4. Company Profiles/Listing
- 11.4.1. Bio-Rad Laboratories
- 11.4.1.1. Overview
- 11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.1.3. Product Benchmarking
- 11.4.1.4. Strategic Initiatives
- 11.4.2. 10x Genomics
- 11.4.2.1. Overview
- 11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.2.3. Product Benchmarking
- 11.4.2.4. Strategic Initiatives
- 11.4.3. Novogene Co, Ltd
- 11.4.3.1. Overview
- 11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.3.3. Product Benchmarking
- 11.4.3.4. Strategic Initiatives
- 11.4.4. Fluidigm
- 11.4.4.1. Overview
- 11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.4.3. Product Benchmarking
- 11.4.4.4. Strategic Initiatives
- 11.4.5. BGI
- 11.4.5.1. Overview
- 11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.5.3. Product Benchmarking
- 11.4.5.4. Strategic Initiatives
- 11.4.6. Illumina, Inc.
- 11.4.6.1. Overview
- 11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.6.3. Product Benchmarking
- 11.4.6.4. Strategic Initiatives
- 11.4.7. Oxford Nanopore Technologies plc.
- 11.4.7.1. Overview
- 11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.7.3. Product Benchmarking
- 11.4.7.4. Strategic Initiatives
- 11.4.8. Pacific Biosciences
- 11.4.8.1. Overview
- 11.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.8.3. Product Benchmarking
- 11.4.8.4. Strategic Initiatives
- 11.4.9. Thermo Fisher Scientific, Inc.
- 11.4.9.1. Overview
- 11.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.9.3. Product Benchmarking
- 11.4.9.4. Strategic Initiatives
- 11.4.10. QIAGEN
- 11.4.10.1. Overview
- 11.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.10.3. Product Benchmarking
- 11.4.10.4. Strategic Initiatives
- 11.4.11. F. Hoffmann La-Roche Ltd.
- 11.4.11.1. Overview
- 11.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 11.4.11.3. Product Benchmarking
- 11.4.11.4. Strategic Initiatives